Werewolf Therapeutics logo

Werewolf TherapeuticsNASDAQ: HOWL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 April 2021

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$129.36 M
-71%vs. 3y high
47%vs. sector
-vs. 3y high
-vs. sector
-58%vs. 3y high
45%vs. sector
-73%vs. 3y high
80%vs. sector

Price

after hours | 6 min ago
$2.96-$0.15(-4.82%)

Dividend

No data over the past 3 years
$1.14 M$710.00 K
$1.14 M-$17.25 M

Analysts recommendations

Institutional Ownership

HOWL Latest News

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
zacks.com08 August 2024 Sentiment: NEGATIVE

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com08 August 2024 Sentiment: POSITIVE

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting –

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
globenewswire.com25 June 2024 Sentiment: POSITIVE

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 -

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers -

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Zacks Investment Research15 April 2024 Sentiment: POSITIVE

There is increasing optimism about the earnings potential of Werewolf Therapeutics (HOWL), leading to its upgrade to a Zacks Rank #2 (Buy) and a potential increase in stock price.

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
Zacks Investment Research12 March 2024 Sentiment: POSITIVE

The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research07 March 2024 Sentiment: POSITIVE

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days
Seeking Alpha06 November 2023 Sentiment: POSITIVE

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of IL-2 selectively near the tumor, minimizing toxicity. Early data from phase 1 trials showed remarkable tolerability and PK/PD, as well as the faintest signals of efficacy.

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
InvestorPlace03 November 2023 Sentiment: POSITIVE

Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company treating patients with advanced or metastatic solid tumors with its interleukin 2 INDUKINE molecule.

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets
Seeking Alpha25 August 2023 Sentiment: POSITIVE

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the pipeline would be WTX-330, which is being advanced in a phase 1 open-label study treating patients with metastatic solid tumors and non-Hodgkin lymphoma. Werewolf has a collaboration agreement with Jazz Pharmaceuticals for the development of JZP898, an interferon alpha INDUKINE molecule, with potential milestone payments of up to $1.26 billion.

What type of business is Werewolf Therapeutics?

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

What sector is Werewolf Therapeutics in?

Werewolf Therapeutics is in the Healthcare sector

What industry is Werewolf Therapeutics in?

Werewolf Therapeutics is in the Biotechnology industry

What country is Werewolf Therapeutics from?

Werewolf Therapeutics is headquartered in United States

When did Werewolf Therapeutics go public?

Werewolf Therapeutics initial public offering (IPO) was on 30 April 2021

What is Werewolf Therapeutics website?

https://werewolftx.com

Is Werewolf Therapeutics in the S&P 500?

No, Werewolf Therapeutics is not included in the S&P 500 index

Is Werewolf Therapeutics in the NASDAQ 100?

No, Werewolf Therapeutics is not included in the NASDAQ 100 index

Is Werewolf Therapeutics in the Dow Jones?

No, Werewolf Therapeutics is not included in the Dow Jones index

When was Werewolf Therapeutics the previous earnings report?

No data

When does Werewolf Therapeutics earnings report?

The next expected earnings date for Werewolf Therapeutics is 14 November 2024